Phillips-Medisize is a global leader in design, development, and manufacturing of drug delivery devices (e.g. pen injectors; auto-injectors; wearable devices; smart, connected devices), with extensive experience partnering with Pharmaceutical and Biotech companies to deliver injectable and diagnostic portfolios to a global market. Using a unique strategy of integrated product development and manufacturing, Phillips-Medisize has helped customers in both the Pharmaceutical and Biotech industry deliver complex technologies to end users, with both reduced time to market and product launch risk.
This approach has allowed Phillips-Medisize, as a partner to these industries, to bring cutting-edge technologies to many leading companies delivering injectable and biotechnology platforms to the market. We will present case studies on how our experiences, technologies, and services have helped global players rapidly commercialize drug delivery solutions, with superior product quality and lower total cost of ownership.
Chief Technology Officer,
As Chief Technology Officer, Bill Welch leads the Phillips-Medisize global pre-production organization, a 700+ person team spanning front-end innovation, development, and new product introduction. Welch’s program-focused organization regularly has more than 50 programs running concurrently along the development and launch continuum, and he leads the company’s global expansion for manufacturing and development.
With nearly 30 years of contract development and manufacturing experience, Welch has a bachelor’s degree from the University of Minnesota at Duluth, serves on the industry advisory board for the Plastics Engineering program at the University of Wisconsin-Stout, and is a board member of an inhaled drug delivery platform company.
Vivek has >25 years global experience in Pharma, Drug Delivery and Med-Tech industry with organizations like Sanofi, BD and Stevanato Group. In his extensive experience in Asia, US and EU markets, Vivek has impacted in roles of global business unit leadership, developing new drug delivery technologies and strategy building. In the Asia market itself, he is well know for establishing the Drug Delivery segment and partnering with Asian pharma for their expansion into international markets.